Gilead 3Q Revenues: $8.3 billion (+37%) 3Q Earnings: $4.6 billion (+69%) YTD Revenues: $24.1 billion (+37%) YTD Earnings: $13.4 billion (+56%) Comments: Antiviral product sales were $7.7 billion in the quarter, up 40% primarily driven by Harvoni  sales of $3.3 billion, partially offset by a decrease in sales of Sovaldi (-48% to $1.5 billion)  as a result of uptake in Harvoni. Atripla sales were $818 million in the quarter, down 9%. Stribild sales were $511 million, up 56%. Complera sales we...